In conclusion, our research showed for the first time that the anti-PCSK9 mAb1 (6 and 10 mg/kg) treatment attenuated the vasculitis via modulating the TLR2 and NF-ƙB pathway in HFD together with zymosan treated mice. The gene discussed is PCSK9; the disease is vasculitis.